Abstract
Src tyrosine kinase, known as a proto-oncogene, participates in many signal pathways to regulate various cellular functions. Abnormal activation of Src is also involved in cancer progression. Autophosphorylation of Src plays a crucial role in its activation. Herein, I have developed an assay platform to screen Src tyrosine kinase inhibitors by analyzing the autophosphorylation of Src. The autophosphorylation reaction was performed in a 96-well format thermocycler and the autophosphorylation of Src was analyzed by dot-blot assay. In this assay platform, the Z`-factor for each plate was greater than 0.49 and the acceptable tolerance of dimethyl sulfoxide was up to 1%. No drift or edge effects was observed. Known kinase inhibitors were used to validate this assay platform. All known Src tyrosine kinase inhibitors exhibited the inhibition of Src kinase activity in the confirmatory assay. The IC50 of Dasatinib and Saracatinib, two potent Src tyrosine kinase inhibitors, measured by this assay platform are 7.7 and 24.4 nM, respectively. Thus, this assay platform can be used to screen Src tyrosine kinase inhibitors for discovery of anti-cancer drug.